By Professor Michael Leonard Friedlander

Journal articles

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P, 2014, 'Incorporation of pazopanib in maintenance therapy of ovarian cancer', Journal of Clinical Oncology, 32, pp. 3374 - 3381, http://dx.doi.org/10.1200/JCO.2014.55.7348

Harter P; du Bois A; WImberger P; Schmalfeldt B; Emons G; Kreienberg R; Hilpert F; Lück HJ; Matulonis U; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Mapherson E; Dougherty B; Juergensmeier JM; Orr M; Ledermann J, 2014, 'Erhaltungstherapie mit Olaparib nach platinhaltiger Re-induktion bei platinsensitivem serösem Ovarialkarzinomrezidiv: eine Placebo-kontrollierte Phase II Studie', Geburtshilfe und Frauenheilkunde, 74, http://dx.doi.org/10.1055/s-0034-1388545

Anuradha S; Webb PM; Blomfield P; Brand AH; Friedlander M; Leung Y; Obermair A; Oehler MK; Quinn M; Steer C; Jordan SJ, 2014, 'Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study', Medical Journal of Australia, 201, pp. 283 - 288, http://dx.doi.org/10.5694/mja14.00132

Meiser B; Price MA; Butow PN; Rahman B; Tucker K; Cheah B; Bickerstaffe A; Hopper J; Phillips KA; Bennett B; Tennant C; Milne RL; Weideman P; Stanhope L; Picken S; Friedlander ML; Goldgar D, 2014, 'Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer', Familial Cancer, 13, pp. 153 - 162, http://dx.doi.org/10.1007/s10689-013-9687-y

Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockler MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).', Journal of Clinical Oncology, 32, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5632

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D; Underhill C, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669

Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; De Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E, 2014, 'Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer', Journal of Clinical Oncology, 32, pp. 1309 - 1316, http://dx.doi.org/10.1200/JCO.2013.51.4240

Davis A; Tinker AV; Friedlander M, 2014, '"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?', Gynecologic Oncology, 133, pp. 624 - 631, http://dx.doi.org/10.1016/j.ygyno.2014.02.038

Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2014, 'Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 25, pp. 143 - 148, http://dx.doi.org/10.1093/annonc/mdt369

Butow PN; Price MA; Bell ML; Webb PM; Defazio A; Friedlander M, 2014, 'Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs', Gynecologic Oncology, 132, pp. 690 - 697, http://dx.doi.org/10.1016/j.ygyno.2014.01.002

Friedlander ML, 2014, 'Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)', Chinese Clinical Oncology, 3, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.11.01

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'Development of the measure of ovarian symptoms and Treatment concerns aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer', International Journal of Gynecological Cancer, 24, pp. 865 - 873, http://dx.doi.org/10.1097/IGC.0000000000000167

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2014, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', The Lancet Oncology, 15, pp. 852 - 861, http://dx.doi.org/10.1016/S1470-2045(14)70228-1

Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT, 2014, 'Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer a reality check: Results of stage 1 of the gynecologic cancer intergroup symptom benefit study', International Journal of Gynecological Cancer, 24, pp. 857 - 864, http://dx.doi.org/10.1097/IGC.0000000000000147

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Ho TW; Ledermann JA, 2014, 'Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)', Gynecologic Oncology, 133, pp. 54 - 55, http://dx.doi.org/10.1016/j.ygyno.2014.03.152

Long A; Toner G; Stockler MR; Thomson DB; Gebski V; Yip S; King M; Friedlander M; Quinn DI; Singhal N; Roncolato F; Grimison P, 2014, 'Anzup 1302: a Randomised Phase 3 Trial of Accelerated Versus Standard Bep Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (P3Bep)', Annals of Oncology, 25, pp. iv303 - iv303, http://dx.doi.org/10.1093/annonc/mdu337.65

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Bennett B; Parry D; Matulonis U, 2014, 'Health-Related Quality of Life (Hrqol) During Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer (Psr Soc) and a Brca Mutation (Brcam)', Annals of Oncology, 25, pp. iv308 - iv308, http://dx.doi.org/10.1093/annonc/mdu338.11

Nomura H; Hanker L; Fabbro M; Rau J; Kim Y; Arija JAA; Friedlander M; Ferrandina G; Vuylsteke P; Colombo N; Malander S; Monk BJ; Petru E; Calvert P; Herzog T; Barrett C; Jobanputra M; Wang Q; Elser G; Du Bois A, 2014, 'Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial', Annals of Oncology, 25, pp. iv307 - iv307, http://dx.doi.org/10.1093/annonc/mdu338.6

Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2014, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, http://dx.doi.org/10.1111/ajo.12281

Sommeijer DW; Sjoquist KM; Friedlander M, 2013, 'Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature', Current Oncology Reports, 15, pp. 541 - 548, http://dx.doi.org/10.1007/s11912-013-0343-3

Thewes B; Bell ML; Butow P; Beith J; Boyle F; Friedlander M; McLachlan SA, 2013, 'Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: Results of a cross-sectional study', Psycho-Oncology, 22, pp. 2797 - 2806, http://dx.doi.org/10.1002/pon.3348

Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN, 2013, 'Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study', Oncologist, 18, pp. 1221 - 1228, http://dx.doi.org/10.1634/theoncologist.2013-0175

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204

Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA, 2013, 'Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham foundation consortium for research into familial breast cancer', Journal of Clinical Oncology, 31, pp. 3920 - 3925, http://dx.doi.org/10.1200/JCO.2013.49.3007

Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; Cuningham K; Hopper JL; Phillips KA, 2013, 'Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers', Medical Journal of Australia, 199, pp. 680 - 683, http://dx.doi.org/10.5694/mja13.10848

Price MA; Butow PN; Bell ML; Webb PM; deFazio A; Friedlander M; Fardell JE, 2013, 'PSYCHOSOCIAL PREDICTORS OF SURVIVAL IN WOMEN WITH INVASIVE OVARIAN CANCER: A POPULATION-BASED PROSPECTIVE STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 91 - 91, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; De Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB, 2013, 'Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study', Clinical Cancer Research, 19, pp. 5485 - 5493, http://dx.doi.org/10.1158/1078-0432.CCR-13-1262

Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359

Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RAEM; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL, 2013, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Journal of Clinical Oncology, 31, pp. 3091 - 3099, http://dx.doi.org/10.1200/JCO.2012.47.8313

Price MA; Bell ML; Sommeijer DW; Friedlander M; Stockler MR; Defazio A; Webb PM; Butow PN, 2013, 'Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life', Gynecologic Oncology, 130, pp. 162 - 168, http://dx.doi.org/10.1016/j.ygyno.2013.03.031

Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA, 2013, 'Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: Time to think differently?', Journal of Clinical Oncology, 31, pp. 2362, http://dx.doi.org/10.1200/JCO.2012.47.7927

Stockler MR; Hilpert F; Friedlander M; King M; Wenzel LB; Lee C; Joly F; De Gregorio N; Arranz Arija JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade Lauraine E, 2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).', Journal of Clinical Oncology, 31, pp. 5542 - 5542, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5542

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Macpherson E; Dougherty B; Jürgensmeier JM; Orr M; Matulonis U, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).', Journal of Clinical Oncology, 31, pp. 5505 - 5505, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5505

Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Bowen K; Fielding A; Domchek SM, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.', Journal of Clinical Oncology, 31, pp. 11024 - 11024, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.11024

Friedlander M; Sjoquist KM; Sommeijer DW; Bailey L; Martyn J; Gillies K; Mileshkin LR; O'Connel R; Gebski V; Vaughan MM; Blomfield P; Beale PJ; Quinn M; Stockler MR; Lombard JM; Hadley AM; Amant F; Edmondson RJ, 2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', Journal of Clinical Oncology, 31, pp. TPS5614 - TPS5614, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps5614

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', Journal of Clinical Oncology, 31, pp. LBA5503 - LBA5503, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba5503

Webber K; Girgis A; Bennett BK; Bonaventura A; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602

Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Webb P, 2013, 'Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study', Gynecologic Oncology, 129, pp. 310 - 317, http://dx.doi.org/10.1016/j.ygyno.2013.02.007

Shen H; Fridley BL; Song H; Lawrenson K; Cunningham JM; Ramus SJ; Cicek MS; Tyrer J; Stram D; Larson MC; Köbel M; Ziogas A; Zheng W; Yang HP; Wu AH; Wozniak EL; Ling Woo Y; Winterhoff B; Wik E; Whittemore AS; Wentzensen N; Palmieri Weber R; Vitonis AF; Vincent D; Vierkant RA; Vergote I; Van Den Berg D; Van Altena AM; Tworoger SS; Thompson PJ; Tessier DC; Terry KL; Teo SH; Templeman C; Stram DO; Southey MC; Sieh W; Siddiqui N; Shvetsov YB; Shu XO; Shridhar V; Wang-Gohrke S; Severi G; Schwaab I; Salvesen HB; Rzepecka IK; Runnebaum IB; Anne Rossing M; Rodriguez-Rodriguez L; Risch HA; Renner SP; Poole EM; Pike MC; Phelan CM; Pelttari LM; Pejovic T; Paul J; Orlow I; Zawiah Omar S; Olson SH; Odunsi K; Nickels S; Nevanlinna H; Ness RB; Narod SA; Nakanishi T; Moysich KB; Monteiro ANA; Moes-Sosnowska J; Modugno F; Menon U; McLaughlin JR; McGuire V; Matsuo K; Mat Adenan NA; Massuger LFAG; Lurie G; Lundvall L; Lubiński J; Lissowska J; Levine DA; Leminen A; Lee AW; Le ND; Lambrechts S; Lambrechts D; Kupryjanczyk J; Krakstad C; Konecny GE; Krüger Kjaer S; Kiemeney LA; Kelemen LE; Keeney GL; Karlan BY; Karevan R; Kalli KR; Kajiyama H; Ji BT; Jensen A; Jakubowska A, 2013, 'Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2629

Permuth-Wey J; Lawrenson K; Shen HC; Velkova A; Tyrer JP; Chen Z; Lin HY; Ann Chen Y; Tsai YY; Qu X; Ramus SJ; Karevan R; Lee J; Lee N; Larson MC; Aben KK; Anton-Culver H; Antonenkova N; Antoniou AC; Armasu SM; Bacot F; Baglietto L; Bandera EV; Barnholtz-Sloan J; Beckmann MW; Birrer MJ; Bloom G; Bogdanova N; Brinton LA; Brooks-Wilson A; Brown R; Butzow R; Cai Q; Campbell I; Chang-Claude J; Chanock S; Chenevix-Trench G; Cheng JQ; Cicek MS; Coetzee GA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Despierre E; Doherty JA; Dörk T; Du Bois A; Dürst M; Easton DF; Eccles D; Edwards R; Ekici AB; Fasching PA; Fenstermacher DA; Flanagan JM; Garcia-Closas M; Gentry-Maharaj A; Giles GG; Glasspool RM; Gonzalez-Bosquet J; Goodman MT; Gore M; Górski B; Gronwald J; Hall P; Halle MK; Harter P; Heitz F; Hillemanns P; Hoatlin M; Høgdall CK; Høgdall E; Hosono S; Jakubowska A; Jensen A; Jim H; Kalli KR; Karlan BY; Kaye SB; Kelemen LE; Kiemeney LA; Kikkawa F; Konecny GE; Krakstad C; Krüger Kjaer S; Kupryjanczyk J; Lambrechts D; Lambrechts S; Lancaster JM; Le ND; Leminen A; Levine DA; Liang D; Kiong Lim B; Lin J; Lissowska J; Lu KH; Lubiński J, 2013, 'Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2613

Olsen CM; Nagle CM; Whiteman DC; Ness R; Pearce CL; Pike MC; Rossing MA; Terry KL; Wu AH; Group S; Risch HA; Yu H; Doherty JA; Chang-Claude J; Hein R; Nickels S; Wang-Gohrke S; Goodman MT; Carney ME; Matsuno RK; Lurie G; Moysich K; Kjaer SK; Jensen A; Hogdall E; Goode EL; Fridley BL; Vierkant RA; Larson MC; Schildkraut J; Hoyo C; Moorman P; Weber RP; Cramer DW; Vitonis AF; Bandera EV; Olson SH; Rodriguez-Rodriguez L; King M; Brinton LA; Yang H; Garcia-Closas M; Lissowska J; Anton-Culver H; Ziogas A; Gayther SA; Ramus SJ; Menon U; Gentry-Maharaj A; Webb PM, 2013, 'Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium', Endocrine-Related Cancer, 20, pp. 251 - 262, http://dx.doi.org/10.1530/ERC-12-0395

Nagle CM; Olsen CM; Ibiebele TI; Spurdle AB; Webb PM, 2013, 'Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis', EUROPEAN JOURNAL OF NUTRITION, 52, pp. 705 - 715, http://dx.doi.org/10.1007/s00394-012-0376-7

Baumbusch LO; Helland A; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; Mitchell G; Fereday S; DeFazio A; Bowtell DDL; Kristensen GB; Lingjærde OC; Børresen-Dale AL, 2013, 'High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0054356

Lee CK; Simes RJ; Brown C; Gebski V; Pfisterer J; Swart AM; Berton-Rigaud D; Plante M; Skeie-Jensen T; Vergote I; Schauer C; Pisano C; Parma G; Baumann K; Ledermann JA; Pujade-Lauraine E; Bentley J; Kristensen G; Belau A; Nankivell M; Canzler U; Lord SJ; Kurzeder C; Friedlander M, 2013, 'A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 24, pp. 937 - 943, http://dx.doi.org/10.1093/annonc/mds538

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204

Couch FJ; Wang X; McGuffog L; Lee A; Olswold C; Kuchenbaecker KB; Soucy P; Fredericksen Z; Barrowdale D; Dennis J; Gaudet MM; Dicks E; Kosel M; Healey S; Sinilnikova OM; Lee A; Bacot F; Vincent D; Hogervorst FBL; Peock S; Stoppa-Lyonnet D; Jakubowska A; Radice P; Schmutzler RK; Domchek SM; Piedmonte M; Singer CF; Friedman E; Thomassen M; Hansen TVO; Neuhausen SL; Szabo CI; Blanco I; Greene MH; Karlan BY; Garber J; Phelan CM; Weitzel JN; Montagna M; Olah E; Andrulis IL; Godwin AK; Yannoukakos D; Goldgar DE; Caldes T; Nevanlinna H; Osorio A; Terry MB; Daly MB; van Rensburg EJ; Hamann U; Ramus SJ; Ewart Toland A; Caligo MA; Olopade OI; Tung N; Claes K; Beattie MS; Southey MC; Imyanitov EN; Tischkowitz M; Janavicius R; John EM; Kwong A; Diez O; Balmaña J; Barkardottir RB; Arun BK; Rennert G; Teo SH; Ganz PA; Campbell I; van der Hout AH; van Deurzen CHM; Seynaeve C; Gómez Garcia EB; van Leeuwen FE; Meijers-Heijboer HEJ; Gille JJP; Ausems MGEM; Blok MJ; Ligtenberg MJL; Rookus MA; Devilee P; Verhoef S; van Os TAM; Wijnen JT; Frost D; Ellis S; Fineberg E; Platte R; Evans DG; Izatt L; Eeles RA; Adlard J; Eccles DM; Cook J; Brewer C; Douglas F; Hodgson S, 2013, 'Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk', PLoS Genetics, 9, http://dx.doi.org/10.1371/journal.pgen.1003212

Friedlander ML; King MT, 2013, 'Patient-reported outcomes in ovarian cancer clinical trials', Annals of Oncology, 24, http://dx.doi.org/10.1093/annonc/mdt474

Hacker NF; Barlow EL; Scurry J; Gebski V; Farrell R; Robertson G; Friedlander ML; Jackson M, 2013, 'Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer', Obstetrics and Gynecology, 121, pp. 765 - 772, http://dx.doi.org/10.1097/AOG.0b013e3182887836

Luk WY; Friedlander M, 2013, 'A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour.', Case Rep Obstet Gynecol, 2013, pp. 492754, http://dx.doi.org/10.1155/2013/492754

Back to profile page